A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Yan Li et al.|Nature Medicine|2021Cited by 365
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementiasFranc Llorens, Inga Zerr, Katrin Thüne et al.|Molecular Neurodegeneration|2017Cited by 268
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burdenJohannes Levin, Simone Baiardi, Corinne Quadalti et al.|Alzheimer s & Dementia|2024Cited by 37
Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter studyNúria Guillén, Albert Lladó, José Contador et al.|European Archives of Psychiatry and Clinical Neuroscience|2023Cited by 14